Molecular Pathology of Lung Cancer

Area of Science:

• Oncology
• Genomics
• Pathology

Background:

• Targetable genomic alterations are essential for guiding lung cancer therapy selection.
• The field of molecular and biomarker testing in lung cancer is rapidly advancing.
• Pathologists require clear guidance on testing procedures and targets for effective patient treatment.

Purpose of the Study:

• To emphasize the importance of identifying targetable genomic alterations in lung cancer.
• To guide pathologists and laboratory personnel on optimal ancillary molecular testing strategies.
• To ensure the provision of clinically relevant genomic information for lung cancer treatment.

Main Methods:

• Review of current guideline statements on molecular testing in lung cancer.
• Focus on the utilization of small biopsy specimens for ancillary testing.
• Emphasis on understanding which specimens to test, how to perform testing, and which targets are critical.

Main Results:

• Genomic alteration identification is a standard of care for lung cancer therapy selection.
• Guidelines exist to assist pathologists in molecular testing of lung cancer specimens.
• Effective testing requires knowledge of specimen types, testing methods, and key genomic targets.

Conclusions:

• Pathologists play a vital role in selecting appropriate molecular tests for lung cancer.
• Adherence to guidelines ensures optimal use of limited patient specimens for genomic analysis.
• Accurate molecular profiling is indispensable for personalized medicine in lung cancer.